Recognizing and managing chronic graft-versus-host disease.
Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that occurs frequently after allogeneic hematopoietic cell transplantation (HCT). Most cases are diagnosed within the first year at a median of 4 to 6 months after HCT, but 5-10% of cases are initially diagnosed beyond the first post-transplant year. Chronic GVHD most often involves the skin and mouth, but almost any other organ system can be involved. Correct diagnosis is critical so that appropriate therapy can be started promptly to minimize symptoms and prevent irreversible organ damage. Initial treatment should be with cortico-steroid-based therapy. Optimal secondary treatment as not been established, although a large number of agents may provide benefits. A 2004 NIH conference focused on development of consensus criteria for chronic GVHD. Six papers published in 2005 and 2006 propose consensus definitions for chronic GVHD diagnosis and scoring, pathology, biomarkers, response criteria, supportive care and design of clinical trials. This review will focus on common clinical presentations and principles for managing chronic GVHD. The most frequently used secondary therapies and ongoing trials are summarized. New concepts from the NIH consensus conference are discussed.
Lee
Stephanie J
SJ
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. sjlee@fhcrc.org
Flowers
Mary E D
ME
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002908:Chronic Disease; D015331:Cohort Studies; D003245:Consensus Statements as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016609:Neoplasms, Second Primary / Q000453:epidemiology; D014184:Transplantation, Homologous / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D003907:Dexamethasone